AI-Driven Lead Optimization Delivers 11B-6, a More Potent HBV Capsid Modulator
- Investigators describe a multi-objective lead-optimization campaign built on the sulfamoylbenzamide (SBA) chemotype exemplified by NVR 3-778, an earlier clinical-stage HBV capsid assembly modulator (CAM).
- An AI-guided computational workflow was integrated with iterative synthesis to simultaneously optimize antiviral potency alongside physicochemical and ADME/drug-like properties across the series.
- The campaign identified 11B-6 as the optimized lead, reported to combine stronger anti-HBV potency with improved drug-like characteristics relative to earlier series analogues.
- Mechanistically, 11B-6 functions as a capsid assembly modulator, engaging the HBV core (capsid) protein to misdirect nucleocapsid assembly and interfere with viral replication.
- The work positions 11B-6 as a candidate for further preclinical evaluation within the sulfamoylbenzamide CAM class for chronic hepatitis B treatment.
What actually catches my eye isn't the potency bump — it's that AI-guided optimization was wired into the synthesis loop, not run as a pre-filter before chemists took over. That's the difference between a screening deck and a real DMTA cycle. Going back to the SBA/NVR 3-778 chemotype rather than hunting a new capsid-binding scaffold is the pragmatic call: the pocket and assembly-misdirection mechanism are already de-risked clinically, so this campaign is buying SAR knowledge instead of paying discovery tax twice. That said, 'improved drug-like properties' is a claim I want backed by real microsomal stability, plasma protein binding, and hERG numbers before I get excited — potency plus a nicer cLogP on paper doesn't guarantee 11B-6 clears whatever tolerability hurdle likely sank NVR 3-778. Worth watching, not yet worth celebrating.